Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
A Feasibility Study of Re-irradiation Using Stereotactic Body Radiation Therapy (SBRT) and Cetuximab for Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Sponsor: Roswell Park Cancer Institute
Terminated
Low accrual
Other terminated trials from Roswell Park Cancer Institute
Other Head and Neck Cancer trials with similar outcome
A NA clinical study on Head and Neck Cancer, this trial is terminated or withdrawn. The trial is conducted by Roswell Park Cancer Institute and has accumulated 7 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Dec 2021 — Jul 2024 [monthly]
Terminated NA
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated NA
-
Jan 2017 — Feb 2017 [monthly]
Terminated NA
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Roswell Park Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .